4DMedical And 2 Other Australian Growth Stocks To Own

Australia’s interest rate now sits at a 15 year high of 4.6%, which makes dependable earnings growth harder to find and more valuable when you do. Higher borrowing costs punish weak balance sheets, yet stronger businesses with solid finances and clear profit expansion stories can still build wealth. This article highlights three Australian high growth potential stocks from our healthy growth screen that fit that profile.

The three stocks covered below are a small sample, with the full healthy high growth screen surfacing 94 more Australian businesses with similar earnings expansion stories and balance sheet strength that are not included here.

If you want to move beyond a short list and identify your own highest conviction ideas, head straight to the Healthy high growth potential screener to filter and analyze the full set of opportunities.

4DMedical (ASX:4DX)

Overview: 4DMedical develops non invasive lung imaging hardware and software that provide quantitative respiratory insights for clinicians, drug developers and screening programs.

Operations: 4DMedical currently generates about A$7.1 million from medical technology R&D of lung function analysis, with roughly A$6.9 million from the United States and A$0.2 million from Australia.

Market Cap: A$2.5b

4DMedical sits squarely in this healthy high growth potential theme because its lung imaging platform ties projected earnings expansion directly to clinically useful respiratory technology.

"Partnership with Philips promised a $10Million USD minimum order commitment contract over the next 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedicals CT:VQ technology as an official product on their catalog in North America."

What happens to 4DMedical’s high margin ambitions if a single key assumption about real world scan volumes or pricing power breaks?

If that question is front of mind, read the full narrative for 4DMedical to see how Philips, capital needs and execution risk could reshape 4DMedical’s next chapter.

Neuren Pharmaceuticals (ASX:NEU)

Overview: Neuren Pharmaceuticals develops treatments for neurological disorders, with DAYBUE for Rett syndrome anchoring its role in the healthy high growth potential theme.

Operations: Neuren generates about A$69.5 million from commercial products, with all reported revenue currently coming from the United States.

Market Cap: A$2.6b

Neuren Pharmaceuticals taps into the healthy high growth potential theme because DAYBUE turns specialist neuroscience research into real world commercial cash flow.

"The expectation of increased diagnosed population and patient uptake of DAYBUE in the U.S. indicates potential revenue growth with more patients getting access to the drug."

What could happen to Neuren’s earnings profile if pricing or access for this single treatment were to shift in an unfavourable direction?

If that concentration risk is what concerns you, read the full narrative for Neuren Pharmaceuticals to see how Neuren Pharmaceuticals could accelerate or stall as DAYBUE’s story evolves.

Megaport (ASX:MP1)

Overview: Megaport runs a global Software Defined Network that lets enterprises quickly spin up on-demand connections between data centers and multiple clouds.

Operations: Megaport generates about A$312 million in revenue, with roughly A$198 million from the Americas, A$70 million from Asia Pacific, and A$44 million from Europe.

Market Cap: A$4.9b

Megaport matters for this healthy high growth potential screen because its SDN platform directly links earnings potential to increasing multi-cloud connectivity demand.

"Megaport's automation, global reach, and software-defined architecture give it significant potential to be the connectivity backbone for AI factories, data-native SaaS, and hybrid enterprise networks."

What happens to Megaport’s long term earnings story if one key assumption about the cost of funding this build out shifts?

If that funding question is on your mind, read the full narrative for Megaport to see how Megaport’s build out risk, pricing power and competitive position could really be shifting.

Seeking Fresh Alternatives Beyond These Three

Fresh opportunities move quickly. The most interesting ideas often gain momentum before headlines catch up, and then the easy entry points start dropping. Check these curated lists and consider them early in your research.

• Track stronger balance sheets and steadier earnings profiles by scanning the curated list of solid balance sheet and fundamentals (11 results) before those stocks are fully caught by the broader market.
• Explore potential cash generating AI trends while they are still under the radar for now by reviewing the curated 37 profitable AI stocks that aren't just burning cash before momentum really builds.
• Look into possible power grid and electrification upgrades by checking the curated 39 power grid technology and infrastructure stocks while it still feels like a specialist corner of the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com